The company has opened new facilities and an innovation center in Singapore, China that will focus on the development of plant-based products.
On Oct. 26, 2017, Roquette announced the opening of previously announced new facilities and an innovation center in Singapore, China. According to the company, the facilities will be focused on plant-based pharma, food, and nutrition products specific to regional health trends.
“As a global business leader, we know that we need to adapt our solutions to the specific needs of the different markets. By expanding our international research capability, we can ensure our products contribute to improving health and well-being of millions of consumers around the world,” said Jean-Marc Gilson, CEO of Roquette, in a company press release. “Our facilities in Singapore will allow us to explore new ways to address specific health and nutrition needs of Asian customers and consumers through plant-based ingredients such as sugar alternatives, vegetal proteins or pharmaceutical excipients, among many others.”
Features of the new facilities include a research laboratory, customer technical services, and a new regional headquarters, and will enable the company to partner with customers, universities, and research institutions for solutions, such as Singapore’s Agency for Science, Technology and Research (A*STAR) or the National University of Singapore.
This latest announcement follows a series of recent global investments by the company, including the September 2017 acquisition of Itacel, previously an excipient division of Blanver, a Brazilian multinational company.
Source: Roquette
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.